AR029622A1 - Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec - Google Patents

Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec

Info

Publication number
AR029622A1
AR029622A1 ARP000101619A ARP000101619A AR029622A1 AR 029622 A1 AR029622 A1 AR 029622A1 AR P000101619 A ARP000101619 A AR P000101619A AR P000101619 A ARP000101619 A AR P000101619A AR 029622 A1 AR029622 A1 AR 029622A1
Authority
AR
Argentina
Prior art keywords
bacteria
produce
gene
mutation
gram
Prior art date
Application number
ARP000101619A
Other languages
English (en)
Spanish (es)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR029622A1 publication Critical patent/AR029622A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP000101619A 1999-04-09 2000-04-07 Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec AR029622A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12868999P 1999-04-09 1999-04-09
US15345399P 1999-09-10 1999-09-10

Publications (1)

Publication Number Publication Date
AR029622A1 true AR029622A1 (es) 2003-07-10

Family

ID=26826843

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101619A AR029622A1 (es) 1999-04-09 2000-04-07 Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec

Country Status (14)

Country Link
US (5) US20070237793A1 (enExample)
EP (5) EP2281833B1 (enExample)
JP (4) JP4892134B2 (enExample)
KR (4) KR20060116041A (enExample)
CN (1) CN1351653A (enExample)
AR (1) AR029622A1 (enExample)
AU (2) AU780887B2 (enExample)
BR (1) BR0009663A (enExample)
CA (1) CA2366520C (enExample)
ES (2) ES2439645T3 (enExample)
HK (1) HK1045856A1 (enExample)
MX (1) MXPA01010207A (enExample)
NZ (2) NZ530012A (enExample)
WO (1) WO2000061724A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4892134B2 (ja) * 1999-04-09 2012-03-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌ワクチン組成物
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
JP4124732B2 (ja) 2001-09-26 2008-07-23 協和醗酵工業株式会社 α１，４−ガラクトース転移酵素およびガラクトース含有複合糖質の製造法
DE60230717D1 (de) * 2002-04-05 2009-02-26 Merial Sas Attenuirte Gram-negative Bakterien
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
ATE486936T1 (de) * 2003-03-05 2010-11-15 Chemo Sero Therapeut Res Inst Verfahren zur herstellung eines heterologen proteins in e. coli
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
EP2073829B1 (en) * 2006-10-05 2012-06-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
JP2011522796A (ja) 2008-05-06 2011-08-04 ニューヨーク ブラッド センター， インコーポレイテッド 抗ウイルス細胞透過性ペプチド
DE102011016772B8 (de) * 2011-04-12 2024-08-14 Mercedes-Benz Group AG Verfahren und Vorrichtung zur Überwachung zumindest eines Fahrzeuginsassen und Verfahren zum Betrieb zumindest einer Assistenzvorrichtung
US9757445B2 (en) 2013-11-01 2017-09-12 Merial Inc. Attenuated Pasteurella multocida vaccines and methods of making and use thereof
ES2945137T3 (es) 2017-02-10 2023-06-28 Epitopix Llc Proteínas y composiciones inmunitarias que contienen proteínas de Pasteurella y métodos de uso
TW202219269A (zh) 2020-09-30 2022-05-16 美國農業部 新型多殺性巴斯德氏菌株及具有ｈｙａＣ與ｎａｎＰ缺失之疫苗
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗
CN113567415A (zh) * 2021-07-05 2021-10-29 广西大学 表面增强拉曼散射结合免疫层析技术检测布鲁氏杆菌方法
CN115925536B (zh) * 2022-08-01 2025-02-28 北京农学院 靶向抑制DksA的小分子抑制剂和应用
CN116593695B (zh) * 2022-12-29 2025-08-05 重庆澳龙生物制品有限公司 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL52815A (en) * 1977-08-24 1983-03-31 Israel State Fowl cholera vaccine and process for producing an attenuated non-virulent strain of pasteurella multocida
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3426532A1 (de) 1984-07-18 1986-01-30 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Verwendung einer dna-sequenz zur expression sowie dna-struktur und expressionsvektor mit der dna-sequenz
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
DK46693D0 (enExample) * 1993-04-23 1993-04-23 Novo Nordisk As
PL170938B1 (pl) * 1991-03-05 1997-02-28 Wellcome Found Sposób wytwarzania szczepionki przeciwko infekcjom Salmonella PL PL
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
WO1994011024A1 (en) * 1992-11-06 1994-05-26 Regents Of The University Of Minnesota Composition protective against p. multocida pasteurellosis infection
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5587305A (en) 1993-12-06 1996-12-24 The United States Of America As Represented By The Department Of Agriculture Pasteurella haemolytica transformants
WO1995020652A1 (de) 1994-01-28 1995-08-03 Medigene Gmbh Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens
DE69535674T2 (de) 1994-08-30 2009-01-02 Ajinomoto Co., Inc. Verfahren zur herstellung von l-valin und l-leucin
KR100445103B1 (ko) * 1994-12-09 2004-12-04 임페리얼 컬리지 이노베이션스 리미티드 유전자의동정
CA2170839A1 (en) * 1995-03-01 1996-09-02 Janet Macinnes Bacterial preparations, method for producing same, and their use as vaccines
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5994066A (en) 1995-09-11 1999-11-30 Infectio Diagnostic, Inc. Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US5925354A (en) * 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US5840556A (en) * 1996-05-08 1998-11-24 The United States Of America As Represented By The Department Of Agriculture Molecular genetic construction of vaccine strains of pasteurellaceae
JPH1075774A (ja) * 1996-05-31 1998-03-24 Akzo Nobel Nv パスツレラ科の弱毒化ｒｔｘ産生細菌
US6020474A (en) 1997-01-15 2000-02-01 Incyte Pharmaceuticals, Inc. ATP synthase subunits
US6673538B1 (en) 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
JP4892134B2 (ja) * 1999-04-09 2012-03-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌ワクチン組成物
AU7131600A (en) 1999-06-21 2001-01-09 North Carolina State University Acid-inducible promoters for gene expression
US6376211B1 (en) 1999-07-12 2002-04-23 Xoma Technology Ltd. Agents and methods for inhibiting F1/F0 ATPase

Also Published As

Publication number Publication date
JP5377433B2 (ja) 2013-12-25
JP2016019528A (ja) 2016-02-04
KR20060116041A (ko) 2006-11-13
US9289486B2 (en) 2016-03-22
US8974798B2 (en) 2015-03-10
CA2366520C (en) 2013-10-01
CN1351653A (zh) 2002-05-29
EP2281834A2 (en) 2011-02-09
EP2281835A2 (en) 2011-02-09
CA2366520A1 (en) 2000-10-19
US20090202594A1 (en) 2009-08-13
HK1045856A1 (zh) 2002-12-13
EP2281834A3 (en) 2011-11-23
AU2005203189B2 (en) 2007-12-20
NZ514883A (en) 2004-03-26
WO2000061724A2 (en) 2000-10-19
EP1860117A2 (en) 2007-11-28
ES2439645T3 (es) 2014-01-24
JP4892134B2 (ja) 2012-03-07
KR20010112937A (ko) 2001-12-22
EP1171577A2 (en) 2002-01-16
EP2281834B1 (en) 2015-03-04
BR0009663A (pt) 2002-04-09
AU4077600A (en) 2000-11-14
EP2281833B1 (en) 2014-07-02
WO2000061724A3 (en) 2001-02-01
US20100322975A1 (en) 2010-12-23
ES2535961T3 (es) 2015-05-19
JP2002541790A (ja) 2002-12-10
NZ530012A (en) 2005-10-28
JP5973634B2 (ja) 2016-08-23
US20120148625A1 (en) 2012-06-14
US20070237793A1 (en) 2007-10-11
JP2013121347A (ja) 2013-06-20
EP2281833A2 (en) 2011-02-09
EP2281835B1 (en) 2013-11-06
EP1860117A3 (en) 2008-09-03
JP2010284165A (ja) 2010-12-24
KR20060134225A (ko) 2006-12-27
KR20070011622A (ko) 2007-01-24
AU2005203189A1 (en) 2005-08-18
AU780887B2 (en) 2005-04-21
US7763262B2 (en) 2010-07-27
EP2281835A3 (en) 2011-11-23
MXPA01010207A (es) 2003-07-21
EP2281833A3 (en) 2011-11-30
US20150182615A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
AR029622A1 (es) Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec
Cornells et al. ymoA, a Yersinia enterocolitica chromosomal gene modulating the expression of virulence functions
Srinivasa Rao et al. Use of proteomics to identify novel virulence determinants that are required for Edwardsiella tarda pathogenesis
Hanley et al. A 55-kilodalton immunodominant antigen of Porphyromonas gingivalis W50 has arisen via horizontal gene transfer
Avila-Calderon et al. Characterization of outer membrane vesicles from Brucella melitensis and protection induced in mice
DE69027313D1 (de) Impfstoffe enthaltende avirulente phop-type mikroorganismen
PT88329A (pt) Bacterias nao virulentas contra infeccoes estreptococicas
ES2097115T3 (es) Procedimiento para la integracion de un gen elegido en el cromosoma de una bacteria y bacteria obtenida por dicho procedimiento.
Tatum et al. Construction and virulence of a Pasteurella multocida fhaB2 mutant in turkeys
US9402889B2 (en) Live, oral vaccine for protection against Shigella dysenteriae serotype 1
AR035745A1 (es) Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerp
Fu et al. Cloning, expression and characterization of a cell wall surface protein, 6-phosphogluconate dehydrogenase, of Haemophilus parasuis
Berthoud et al. Characterization of Aqx and its operon: the hemolytic RTX determinant of Actinobacillus equuli
KR20030032948A (ko) 독성 유전자, 단백질, 및 그 용도
Sousa Pathogenicity mechanisms of prokaryotic cells: an evolutionary view
BRPI0309001A2 (pt) bactérias gram-negativas atenuadas
JPH11514878A (ja) アクチノバシラス・プリゥロニュウモニエｒｔｘ毒素ａｐｘに対する免疫
Schönecker et al. Trueperella pecoris sp. nov. isolated from bovine and porcine specimens
CY1108972T1 (el) Εξασθενημενα αρνητικα κατα gram βακτηρια
Heinzen Intracellular development of Coxiella burnetii
FASAEI et al. Site-directed mutagenesis in Brucella abortus S19 by overlap extension PCR-based procedure
Frey RTX-toxins in Actinobacillus pleuropneumoniae and their potential role in virulence
Ruffin et al. Transposon mutagenesis of Mycoplasma gallisepticum by conjugation with Enterococcus faecalis and determination of insertion site by direct genomic sequencing
BR9714904A (pt) Vacina antìgena homóloga e método de fazer amesma
Siddaramappa Histophilus somni genomics and genetics

Legal Events

Date Code Title Description
FB Suspension of granting procedure